Sociedad Americana de Hirudoterapia

The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations

Review published in Interv Cardiol Clin (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosSergie Z et al. · Interv Cardiol Clin, 2012

Abstract

The incidence of ST-segment elevation myocardial infarction (STEMI) is a common, albeit declining, manifestation of coronary heart disease. Significant improvements in cardiovascular outcomes and mortality in STEMI patients have occurred in recent years, reflecting evolution in the understanding of the pathophysiological mechanisms and therapeutic targets of this disease. Nonetheless, the risks of recurrent ischemia and bleeding complications in this population remain substantial. This review focuses on the adjunctive anticoagulant agents used in the management of STEMI. Major insights from the HORIZONS-AMI trial regarding the impact of bivalirudin on both hemorrhagic and ischemic outcomes in STEMI patients are discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Resumen

The incidence of ST-segment elevation myocardial infarction (STEMI) is a common, albeit declining, manifestation of coronary heart disease.

Por qué esto importa para la hirudoterapia

This review examines adjunctive anticoagulant agents used in the management of ST-segment elevation myocardial infarction (STEMI), including insights from the HORIZONS-AMI trial regarding the impact of bivalirudin on both hemorrhagic and ischemic outcomes. As a review of anticoagulation strategies in interventional cardiology, it addresses clinical pharmacotherapy without involving leeches, leech therapy, or leech-derived molecules. The abstract provides no information linking bivalirudin to hirudin, the leech secretome, or any aspect of hirudotherapy. Consequently, this article has no demonstrable relevance to ASH's domain beyond the general topic of anticoagulant pharmacotherapy.

Citación

The Use of Bivalirudin in ST-Segment Elevation Myocardial Infarction: Advantages and Limitations.

Sergie Z et al. · Interv Cardiol Clin, 2012

DOI

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug PipelineDrug DevelopmentDirect Thrombin InhibitorsClinical EvidenceClinical ApplicationsHirudinAnticoagulation CompoundsBivalirudinHemostasisCardiovascularCardiologyOtolaryngology

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.